Catalyst Pharmaceuticals Inc (CPRX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Catalyst Pharmaceuticals Inc (CPRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10052
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Catalyst Pharmaceuticals Inc (Catalyst) is a biopharmaceutical company that develops prescription drugs targeting rare neurological and neuromuscular diseases. The company focuses on specific conditions such as infantile spasms, complex partial seizures, Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), downbeat nystagmus and Tourette syndrome. Its product portfolio includes Firdapse, a proprietary form of amifampridine phosphate for the treatment of LEMS, CMS and myasthenia gravis; CPP-115, a GABA aminotransferase inhibitor for central nervous system (CNS) indications, such as infantile spasms, epilepsy and Tourette syndrome; and CPP-109, a generic version of Sabril for Tourette’s disorder. Catalyst is headquartered in Coral Gables, Florida, the US.

Catalyst Pharmaceuticals Inc (CPRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Catalyst Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Catalyst Pharma Amends Licensing Agreement with BioMarin Pharmaceutical 11
Equity Offering 13
Catalyst Pharma Raises USD57.5 Million in Public Offering of Shares 13
Catalyst Pharma Raises USD37.4 Million in Public Offering of Shares 15
Catalyst Pharma Completes Public Offering Of Shares For US$28.7 Million 17
Catalyst Pharma Completes Public Offering Of Shares For US$15 Million 19
Catalyst Pharma Completes Private Placement Of Shares For US$1.1 Million Upon Exercise Of Warrants 20
Catalyst Pharma Completes Public Offering Of Shares For US$6 Million 21
Catalyst Pharma Partners Completes Public Offering Of Units For US$4.8 Million 22
Catalyst Pharmaceuticals Inc – Key Competitors 24
Catalyst Pharmaceuticals Inc – Key Employees 25
Catalyst Pharmaceuticals Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Nov 07, 2018: Catalyst Pharmaceuticals announces third quarter 2018 financial results and provides corporate update 27
Aug 07, 2018: Catalyst Pharmaceuticals Announces Second Quarter 2018 Financial Results and Provides Corporate Update 29
May 09, 2018: Catalyst Pharmaceuticals Announces First Quarter 2018 Financial Results and Provides Corporate Update 31
Mar 14, 2018: Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update 32
Nov 08, 2017: Catalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides Corporate Update 34
Aug 09, 2017: Catalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update 35
May 10, 2017: Catalyst Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update 37
Mar 15, 2017: Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update 38
Corporate Communications 40
Aug 20, 2018: Catalyst Pharmaceuticals names Dr. Stanley Iyadurai as vice president of clinical development 40
Aug 06, 2018: Catalyst Pharmaceuticals expands commercial leadership team 41
Oct 26, 2017: Catalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of Directors 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Catalyst Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Catalyst Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Catalyst Pharma Amends Licensing Agreement with BioMarin Pharmaceutical 11
Catalyst Pharma Raises USD57.5 Million in Public Offering of Shares 13
Catalyst Pharma Raises USD37.4 Million in Public Offering of Shares 15
Catalyst Pharma Completes Public Offering Of Shares For US$28.7 Million 17
Catalyst Pharma Completes Public Offering Of Shares For US$15 Million 19
Catalyst Pharma Completes Private Placement Of Shares For US$1.1 Million Upon Exercise Of Warrants 20
Catalyst Pharma Completes Public Offering Of Shares For US$6 Million 21
Catalyst Pharma Partners Completes Public Offering Of Units For US$4.8 Million 22
Catalyst Pharmaceuticals Inc, Key Competitors 24
Catalyst Pharmaceuticals Inc, Key Employees 25
Catalyst Pharmaceuticals Inc, Subsidiaries 26

List of Figures
Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Catalyst Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Catalyst Pharmaceuticals Inc (CPRX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Senetas Corporation Limited:企業の戦略・SWOT・財務分析
    Senetas Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Senetas Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Sinopac Financial Holdings Company Limited:企業の戦略・SWOT・財務分析
    Sinopac Financial Holdings Company Limited - Strategy, SWOT and Corporate Finance Report Summary Sinopac Financial Holdings Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • PEP-Therapy SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary PEP-Therapy SAS (PEP-Therapy) is a medical biotechnology company that develops targeted therapies for the treatment of cancer. The company develops cell penetrating and interfering peptides for the intracellular delivery of targeted therapies. Its pipeline products include PEP-010. PEP-Thera …
  • Kahve Dunyasi:企業の戦略・SWOT・財務分析
    Kahve Dunyasi - Strategy, SWOT and Corporate Finance Report Summary Kahve Dunyasi - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Bioton SA (BIO):企業の戦略的SWOT分析
    Bioton SA (BIO) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Epiroc AB (EPI A):企業の財務・戦略的SWOT分析
    Epiroc AB (EPI A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Jiangsu Jiuding New Material Co Ltd (002201):企業の財務・戦略的SWOT分析
    Jiangsu Jiuding New Material Co Ltd (002201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • United Technologies Corporation:企業の戦略・SWOT・財務情報
    United Technologies Corporation - Strategy, SWOT and Corporate Finance Report Summary United Technologies Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • LG International Corp:企業のM&A・事業提携・投資動向
    LG International Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's LG International Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Acxiom Corporation:企業の戦略・SWOT・財務情報
    Acxiom Corporation - Strategy, SWOT and Corporate Finance Report Summary Acxiom Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • TIBCO Software, Inc.:企業の戦略・SWOT・財務情報
    TIBCO Software, Inc. - Strategy, SWOT and Corporate Finance Report Summary TIBCO Software, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Bio-Modeling Systems SAS-製薬・医療分野:企業M&A・提携分析
    Summary Bio-Modeling Systems SAS (BM Systems) is a mechanism based medicine company which discovers and develops novel diagnostic, therapeutic and prevention solutions. The company owns an operational mechanisms-based medicine platform known as Computer-Assisted Deductive Integration (CADI), which i …
  • Tanabe Research Laboratories USA Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Tanabe Research Laboratories USA Inc (Tanabe Research Laboratories USA), a subsidiary of Mitsubishi Tanabe Pharma Corp is a healthcare research center that discovers and develops biological drugs. The laboratory conducts research on metabolics, immunology and inflammation. Its products are u …
  • University of California Los Angeles-医療機器分野:企業M&A・提携分析
    Summary University of California Los Angeles (UCLA) a subsidiary of University of California is an educational service provider that offers undergraduate education, graduate, professional education and continuing education. The university’s services include support services, campus services, graduat …
  • TSO3 Inc (TOS)-医療機器分野:企業M&A・提携分析
    Summary TSO3 Inc (TSO3) is a medical device company that designs develops, manufactures, markets and licenses sterilization processes for heat-sensitive medical devices. The company’s area of focus is sterile processing, which provides a replacement solution to other low temperature sterilization pr …
  • Ajinomoto Co., Inc.:企業の戦略・SWOT・財務分析
    Ajinomoto Co., Inc. - Strategy, SWOT and Corporate Finance Report Summary Ajinomoto Co., Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Mentor Graphics Corporation:企業の戦略・SWOT・財務分析
    Mentor Graphics Corporation - Strategy, SWOT and Corporate Finance Report Summary Mentor Graphics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Laboratory Corp of America Holdings (LH):医療機器:M&Aディール及び事業提携情報
    Summary Laboratory Corp of America Holdings (LabCorp) is a provider of clinical laboratory services and end-to-end drug development support. It focuses on the development and commercialization of a wide range of diagnostic technologies and testing services. The company offers clinical diagnostics la …
  • Lund University-製薬・医療分野:企業M&A・提携分析
    Summary Lund University (LNU) is an educational service provider that offers master and bachelor programmes. It offers education and research in the areas of engineering, economics and management, science, law, social sciences, medicine, humanities, theology, fine art, music and others. The universi …
  • Attunity Ltd (ATTU):企業の財務・戦略的SWOT分析
    Summary Attunity Ltd (Attunity) is a technology company that provides data management software, cloud database replication solutions, and google cloud database tools. The company provides data management software solutions that enable access, sharing, management, and distribution of data. It offers …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆